Posted by Michael Wonder on 30 Apr 2024
Dermavant announces FDA acceptance of supplemental new drug application for Vtama (tapinarof) 1% cream for the treatment of atopic dermatitis in adults and children 2 years of age and older
29 April 2024 - FDA PDUFA action expected in Q4, 2024.
Dermavant Sciences today announced that the US FDA accepted the company’s supplemental new drug application for Vtama (tapinarof) 1% cream for the topical treatment of atopic dermatitis in adults and children 2 years of age and older.
